Immunological Processes in the Vascular Wall

  • M. D. Kazatchkine
  • P. S. Seifert
  • U. E. Nydegger

Abstract

Many mechanisms may be involved in the mediation of immunologically induced vascular injury. These mechanisms can be classified as humoral or cellular (Table 26.1). Humoral mechanisms involve deposition or in situ formation of immune complexes and the intravascular activation of complement. Cellular mechanisms lead to granulomatous reactions. This chapter will review the pathophysiology of vascular injury mediated by immune complexes, complement and specific and non-specific cellular effector mechanisms. Some of the functional and immunological characteristics of endothelial cells will also be considered, since the clinical features of inflammatory vascular injury depend to a large extent on the absence (as in post-capillary venules and glomerular capillaries) or presence (as in arteries) of an intact non-fenestrated continuous layer of endothelial cells.

Keywords

Lipase Catalase Fibrinogen Ferritin PGE2 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Asch AS, Kinoshita T, Jaffe EA, Nussenzweig V (1986) Decay-accelerating factor is present on cultured human umbilical vein endothelial cells. J Exp Med 163:221–226PubMedCrossRefGoogle Scholar
  2. 2.
    Arnaout MA, Hakim RM, Todd RF III, Dana N, Colten HR (1985) Increased expression of an adhesion- promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 312:457–462PubMedCrossRefGoogle Scholar
  3. 3.
    Babior BM (1980) Oxygen-dependent microbial killing by phagocytes. N Engl J Med 298:659–721CrossRefGoogle Scholar
  4. 4.
    Bevilacqua MP, Pober JS, Wheeler ME et al. (1985) Interleukin-1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte cell lines. J Clin Invest 76:2003–2011PubMedCrossRefGoogle Scholar
  5. 5.
    Bevilacqua MP, Schleef RR, Gimbrone MA et al. (1986) Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin-1. J Clin Invest 78:587–591PubMedCrossRefGoogle Scholar
  6. 6.
    Bhakdi S, Tranum-Jensen J (1983) Membrane damage by complement. Biochim Biophys Acta 737:343–372PubMedGoogle Scholar
  7. 7.
    Biesecker G, Katz S, Koffler D (1981) Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis. J Exp Med 154:1779–1794PubMedCrossRefGoogle Scholar
  8. 8.
    Biesecker G, Lavin L, Ziskind M et al. (1982) Cutaneous localization of the membrane attack complex in discoid and systemic lupus erythematosus. N Engl J Med 306:264–270PubMedCrossRefGoogle Scholar
  9. 9.
    Border WA, Ward HJ, Kamil ES et al. (1982) Induction of membranous nephropathy in rabbits by administration of an exogenic cationic antigen: demonstration of a pathogenic role for electrical charge. J Clin Invest 69:451–461PubMedCrossRefGoogle Scholar
  10. 10.
    Camussi G, Brentsens JR, Kerjashchki D et al. (1985) Antibody-induced redistribution of Heyman’s antigen on the surface of visceral glomerular epithelial cells in Lewis rats. Kidney Int. 27:207 (abstract)Google Scholar
  11. 11.
    Cerilli J, Brasile L, Galousis T et al. (1985) The vascular endothelial cell antigen system. Transplantation 39(3):286–289PubMedCrossRefGoogle Scholar
  12. 12.
    Chenoweth DE, Hugli TE (1978) Demonstration of a specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci USA 75:3943–3947PubMedCrossRefGoogle Scholar
  13. 13.
    Chenoweth DE, Hugli TE (1982) Assays for chemotactic factors and anaphylatoxins. In: Nakamura RM, Dito WR, Tucker ES III (eds) Immunologic analysis: recent progress in diagnostic laboratory immunology. Masson, New York, pp 227–237Google Scholar
  14. 14.
    Chenoweth DE, Cheung AK, Ward DM et al. (1983) Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes. Kidney Int 24:770–774PubMedCrossRefGoogle Scholar
  15. 15.
    Cines DB, Lyss AP, Reeber M et al. (1983) Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus. J Clin Invest 73:611–625CrossRefGoogle Scholar
  16. 16.
    Cochrane CG, Weigle WO (1958) The cutaneous reaction to soluble antigen-antibody complexes. J Exp Med 108:591–607PubMedCrossRefGoogle Scholar
  17. 17.
    Cochrane CG, Koffler D (1973) Immune complex disease in experimental animals and man. Adv Immunol 16:185–215PubMedCrossRefGoogle Scholar
  18. 18.
    Collins T, Lapierre LA, Fiers W et al. (1986) Recombinant human tumor necrosis factors increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci USA 83:446–450PubMedCrossRefGoogle Scholar
  19. 19.
    Cornacoff JB, Hebert LA, Smead WL et al. (1983) Primate erythrocyte immune complex clearing mechanism. J Clin Invest 71:236–247PubMedCrossRefGoogle Scholar
  20. 20.
    Cotran RS, Gimbrone MA Jr, Bevilacqua MP et al. (1986) Induction and detection of a human endothelial activation antigen in vivo. J Exp Med 164:661–666PubMedCrossRefGoogle Scholar
  21. 21.
    Couser WG (1985) Mechanisms of glomerular injury in immune-complex disease. Kidney Int 28:569–583PubMedCrossRefGoogle Scholar
  22. 22.
    Couser WG, Baker PJ, Adler S (1985) Complement and the direct mediation of immune glomerular injury: a new perspective. Kidney Int 28:879–890PubMedCrossRefGoogle Scholar
  23. 23.
    Craddock PR, Hammerschmitt DE, White JG et al. (1977) Complement (C5a)-induced granulocyte aggregation in vitro. J Clin Invest 60:260–264PubMedCrossRefGoogle Scholar
  24. 24.
    Daha MR, Van Es LA (1979) Further evidence for the antibody nature of C3 nephritic factor (C3Nef). J Immunol 123:755–758PubMedGoogle Scholar
  25. 25.
    Davies Ph, Bailey PJ, Goldenberg MM (1984) The role of arachidonic acid oxygenation products in pain and inflammation. Ann Rev Immunol 2:335–358CrossRefGoogle Scholar
  26. 26.
    Dinarello CA (1984) Interleukin-1 and the pathogenesis of the acute phase response. N Engl J Med 311:1413–1418PubMedCrossRefGoogle Scholar
  27. 27.
    Duffy J, Lidsky MD, Sharp JJ et al. (1976) Polyarthritis, polyarteritis and hepatitis B. Medicine 55:19–35PubMedCrossRefGoogle Scholar
  28. 28.
    Durum SK, Schmidt JA, Oppenheim JJ (1985) Interleukin-1: an immunological perspective. Ann Rev Immunol 3:263–287CrossRefGoogle Scholar
  29. 29.
    Edwards RL, Ewan VA, Rickies FR (1986) Macrophage procoagulants, fibrin deposition and the inflammatory response. In: Phillips SM, Escobar MR (eds) Hypersensitivity, the reticuloendothelial system, a comprehensive treatise. Plenum, New York, pp 233–266Google Scholar
  30. 30.
    Emancipator SN, Lamm ME (1986) Pathways of tissue injury initiated by humoral immune mechanisms. Lab Invest 54:475–478PubMedGoogle Scholar
  31. 31.
    Fearon DT (1978) Regulation by membrane sialic acid of beta-l-H-dependent decay association of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci USA 75:1971–1975PubMedCrossRefGoogle Scholar
  32. 32.
    Fearon DT, Collins LA (1983) Increased expression of C3b receptors on polymorphonuclear leukocytes induced by chemotactic factors and by purification procedures. J Immunol 130:370–375PubMedGoogle Scholar
  33. 33.
    Fearon DT, Wong WW (1983) Complement ligand-receptor interactions that mediate biological responses. Ann Rev Immunol 1:243–272CrossRefGoogle Scholar
  34. 34.
    Fernandez HN, Henson PM, Otani A et al. (1978) Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under simulated in vivo conditions. J Immunol 120:109–116PubMedGoogle Scholar
  35. 35.
    Fischer A, Seger R, Durandy A et al. (1985) Deficiency of the adhesive protein complex lymphocyte function antigen 1, complement receptor type 3, glycoprotein p150,95 in a girl with recurrent bacterial infections. Effects on phagocytic cells and lymphocyte functions. J Clin Invest 76:2385–2392PubMedCrossRefGoogle Scholar
  36. 36.
    Ford PM, Kosatka I (1981) A mechanism of enhancement of immune complex deposition following in situ immune complex formation in the mouse glomerulus. Immunology 43:433–438PubMedGoogle Scholar
  37. 37.
    Frank MM, Lawley T, Hamburger MI et al. (1983) Immunoglobulin G Fc receptor-mediated clearance in autoimmune disease. Ann Intern Med 98:206–218PubMedGoogle Scholar
  38. 38.
    Gallo GR, Caulin-Glaser T, Lamm ME (1981) Charge of circulating immune complexes as a factor in glomerular basement membrane localization in mice. J Clin Invest 67:1305–1313PubMedCrossRefGoogle Scholar
  39. 39.
    Gamble JR, Harlan JM, Klebanoff SJ et al. (1985) Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 82:8667–8671PubMedCrossRefGoogle Scholar
  40. 40.
    Germuth FG Jr, Rodriguez E (1973) Immunopathology of the renal glomerulus. Immune complex deposit and antibasement membrane disease. Little, Brown, BostonGoogle Scholar
  41. 41.
    Gleichmann E, Issa P, Vanelven E et al. (1978) The chronic graft-versus-host reaction: a lupus erythematosus like syndrome caused by abnormal T-B cell interactions. Clin Rheum Dis 4:587–602Google Scholar
  42. 42.
    Griffin JA, Griffin FM Jr (1979) Augmentation of macrophage complement receptor function in vitro. J Exp Med 150:653–675PubMedCrossRefGoogle Scholar
  43. 43.
    Griffin FM (1982) Mononuclear cell phagocyte mechanisms and host defense. In: Gallin JI, Fauci AS (eds) Advances in host-defense mechanisms. Raven Press, New York pp 31–55Google Scholar
  44. 44.
    Groenwegen G, Buurman WA, Vander Unden CJ (1985) Lymphokine dependence of in vivo expression of MHC class II antigens by endothelium. Nature 316:361–363CrossRefGoogle Scholar
  45. 45.
    Hansch GM, Hammer CH, Vanguri P et al. (1981) Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci USA 78:5118–5121PubMedCrossRefGoogle Scholar
  46. 46.
    Harlan JM (1985) Leukocyte-endothelial interactions. Blood 65:513–525PubMedGoogle Scholar
  47. 47.
    Harkiss GD, Brown DL, Evans DB (1975) Longitudinal study of circulating immune complexes in a patient with staphylococcus albus-induced shunt nephritis. Clin Exp Immunol 24:396–400Google Scholar
  48. 48.
    Havemann K, Janoff A (1978) Neutral proteases of human polymorphonuclear leukocytes. Urban and Schwarzenberg, Baltimore and MunichGoogle Scholar
  49. 49.
    Hinglais N, Kazatchkine MD, Bhakdi S et al. (1986) Immunohistochemical study of the C5b-9 complex of complement in normal and diseased human kidneys: diversity in localization and potential role in tissue damage. Kidney Int 30:399–410PubMedCrossRefGoogle Scholar
  50. 50.
    Hugli TE (1986) Biochemistry and biology of anaphylatoxins. Complement 3:111–127PubMedGoogle Scholar
  51. 51.
    Izui S, Lambert PH, Fournie GJ et al. (1977) Features of systemic lupus erythematosus in mice injected with bacterial lipopolysaccharides: identification of circulating DNA and renal localization of DNA-anti- DNA complexes. J Exp Med 145:1115–1123PubMedCrossRefGoogle Scholar
  52. 52.
    Johnson KJ, Wilson BS, Till GO et al. (1984). Acute lung injury in rat caused by immunoglobulin A immune complexes. J Clin Invest 74:358–369PubMedCrossRefGoogle Scholar
  53. 53.
    Kauffmann RH, Herrmann WA, Meyer CJLM et al. (1980) Circulating and tissue-bound immune complexes in allergic vasculitis: relationship between immunoglobulin class and clinical features. Clin Exp Immunol 41:459–470PubMedGoogle Scholar
  54. 54.
    Kauffmann RH, Herrmann WA, Meyer CJLM et al. (1980) Circulating IgA-immune complexes in Henoch- Schönlein purpura. Am J Med 69:859–866PubMedCrossRefGoogle Scholar
  55. 55.
    Kauffmann RH, Thompson J, Valentijn RM et al. (1981) The clinical implications and the pathogenetic significances of circulating immune complexes in infective endocarditis. Am J Med 71:17–25PubMedCrossRefGoogle Scholar
  56. 56.
    Kauffmann RH, Valentijn RM (1982) The spectrum of circulating immune complexes in various forms of systemic small vessel vasculitis. Neth J Med 25:193–201PubMedGoogle Scholar
  57. 57.
    Kazatchkine MD, Fearon DT, Silbert JE et al. (1979) Surface-associated heparin inhibits zymosan-induced activation of the human alternative pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med 150:1202–1215PubMedCrossRefGoogle Scholar
  58. 58.
    Kazatchkine MD, Fearon DT, Appay C et al. (1982) Immunohistochemical study of the human glomerular C3b receptor in normal kidney and in seventy five cases of renal diseases: loss of C3b receptor antigen in focal hyalinosis and in proliferative nephritis of SLE. J Clin Invest 69:900–912PubMedCrossRefGoogle Scholar
  59. 59.
    Kazatchkine MD, Nydegger UE (1982) The human alternative complement pathway: biology and immu- nopathology of activation and regulation. Prog Allergy 30:193–234PubMedGoogle Scholar
  60. 60.
    Kazatchkine MD, Nydegger UE (1986) Complement mediated injury. In: Phillips SM, Escobar MR (eds) The reticuloendothelial system, a comprehensive treatise, Plenum, New York, pp 173–196Google Scholar
  61. 61.
    Klebanoff SJ, Clark RA (1978) The neutrophil. North- Holland, AmsterdamGoogle Scholar
  62. 62.
    Klebanoff SJ (1982) Oxygen dependent cytotoxic mechanisms of phagocytes. In: Gallin JI, Fauci AS (eds) Advances in host-defense mechanisms. Raven Press, New York, pp 111–162Google Scholar
  63. 63.
    Larsen GL, Mitchell BC, Henson PM (1981) The pulmonary response of C5 sufficient and deficient mice to immune complexes. Annu Rev Respir Dis 123:434–439Google Scholar
  64. 64.
    Laude M, Haeffner-Cavaillon N, Fischer E et al. (1985) Human C3 and C3a stimulate IL-1 secretion by cultured human monocytes. Complement 2:48 (abstract)Google Scholar
  65. 65.
    Law SK, Levine RP (1977) Interaction between the third complement protein and cell surface macromolecules. Proc Natl Acad Sci USA 74:2701–2704PubMedCrossRefGoogle Scholar
  66. 66.
    Lynch JM, Worthen GS, Henson PM (1984) Platelet-activating factor. In: Buckle DR, Smith H (eds) Development of anti-asthma drugs. Butterworth, London, pp 73–88Google Scholar
  67. 67.
    Madalinski K, Bragiel I (1979) HbsAg immune complexes in the course of infection with hepatitis B virus. Clin Exp Immunol 36:371–378PubMedGoogle Scholar
  68. 68.
    March CJ, Mosley B, Larsen A et al. (1985) Cloning sequence and expression of two distinct human interleukin-1 complementary DNAs, Nature 315:641–647PubMedCrossRefGoogle Scholar
  69. 69.
    Miossec P, Ziff M (1986) Immune interferon enhances the production of interleukin 1 by human endothelial cells stimulated with polysaccharide. J Immunol 137:2848–2852PubMedGoogle Scholar
  70. 70.
    Mollnes TE, Lea T, Mellbye OJ et al. (1986) Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum 29:715–721PubMedCrossRefGoogle Scholar
  71. 71.
    Moore KL, Andreoli SP, Esmon NL et al. (1987) Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 59:124–130CrossRefGoogle Scholar
  72. 72.
    Nawroth PP, Bank I, Handley D et al. (1986) Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin-1. J Exp Med 163:1363–1375PubMedCrossRefGoogle Scholar
  73. 73.
    Nawroth PP, Handley DA, Esmon CT et al. (1986) Interleukin-1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 83:3460–3464PubMedCrossRefGoogle Scholar
  74. 74.
    Nicholson-Weller A, Burge J, Fearon DT et al. (1982) Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 129:184–189PubMedGoogle Scholar
  75. 75.
    Nydegger UE, Kazatchkine MD (1986) Modulation by complement of immune complex processing in health and disease in man. Prog Allergy 39:361–392PubMedGoogle Scholar
  76. 76.
    Paul LC, Carpenter CB (1980) Antibodies against renal endothelial alloantigens. Transplant Proc 12:43–48PubMedGoogle Scholar
  77. 77.
    Platt JL, Lebien TW, Michael AF (1982) Interstitial mononuclear cell populations in renal graft rejection. Identification by monoclonal antibodies in tissue sections. J Exp Med 155:17–30PubMedCrossRefGoogle Scholar
  78. 78.
    Pober JS, Collins T, Gimbrone MA et al. (1986) Inducible expression of class II major histocompatibility complex antigens and the immunogenicity of vascular endothelium. Transplantation 41 (2): 141–146PubMedCrossRefGoogle Scholar
  79. 79.
    Pober JS, Gimbrone MA Jr, Cotran RS et al. (1983) Ia expression by vascular endothelium is inducible by activated T cells and by human gamma interferon. J Exp Med 147:1339–1353CrossRefGoogle Scholar
  80. 80.
    Pommier CG, Inada S, Fries LG et al. (1983) Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. J Exp Med 157:1844–1854PubMedCrossRefGoogle Scholar
  81. 81.
    Pommier CG, O’Shea, Chuseo T et al. (1984) Studies on the fibronectin receptors of human peripheral blood leucocytes. J Exp Med 159:137–151PubMedCrossRefGoogle Scholar
  82. 82.
    Ramm LE, Whitlow MB, Koski CL et al. (1983) Elimination of complement channels from the plasma membranes of U937, a nucleated mammalian cell line: temperature dependence of the elimination rate. J Immunol 131:1411–1415PubMedGoogle Scholar
  83. 83.
    Reinherz EL, Schlossmann SF (1980) The differentiation and function of human T lymphocytes: a review. Cell 19:821–825PubMedCrossRefGoogle Scholar
  84. 84.
    Rinaldo JE, Rodgers R (1982) Adult respiratory distress syndrome: changing concepts of lung injury and repair. N Engl J Med 396:900–909CrossRefGoogle Scholar
  85. 85.
    Rosenfeld SI, Packman CH, Leddy JP (1983) Inhibition of the lytic action of cell bound terminal complement components by human high density lipoproteins and apoproteins. J Clin Invest 795–808Google Scholar
  86. 86.
    Ross GD, Cain JA, Lachmann PJ (1985) Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin and functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for C’C3b. J Immunol 134:3307–3315PubMedGoogle Scholar
  87. 87.
    Ross GD, Cain JA, Myones BL (1987) Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement 4:61–74PubMedGoogle Scholar
  88. 88.
    Rossi V, Brevario F, Ghezzi P et al. (1985) Prostaglandin synthesis induced in vascular cells by interleukin 1. Science 229:174–176PubMedCrossRefGoogle Scholar
  89. 89.
    Rothlein R, Dustin ML, Marlin SD et al. (1986) A human intracellular adhesion molecule (ICAM-1) distinct from LFA1. J Immunol 137:1270–1274PubMedGoogle Scholar
  90. 90.
    Sachs T, Moldon CF, Craddock PR et al. (1978) Oxygen radical mediates endothelial cell damage by complement stimulated granulocytes. An in vitro model of immune vascular damage. J Clin Invest 61:1161–1167CrossRefGoogle Scholar
  91. 91.
    Sanchez-Madrid F, Nagy JA, Robbins P et al. (1983) A human leukocyte differentiation antigen family with distinct alpha subunits and a common beta subunit. J Exp Med 158:1785–1803PubMedCrossRefGoogle Scholar
  92. 92.
    Schifferli JA, Peters DK (1983) Complement, the immune complex lattice and the pathophysiology of complement deficiency syndromes. Lancet II:957–959PubMedCrossRefGoogle Scholar
  93. 93.
    Schifferli JA, Steiger G, Hauptmann G et al. (1985) Formation of soluble immune complexes by complement in sera of patients with various hypo-complementemic states: difference between inhibition of immune precipitation and solubilization. J Clin Invest 76:2127–2133PubMedCrossRefGoogle Scholar
  94. 94.
    Schifferli JA, Peters KD (1986) The role of complement and its receptor in the elimination of immune complexes. N Engl J Med 315:488–495PubMedCrossRefGoogle Scholar
  95. 95.
    Schmidt JA, Mizel SB, Cohen D et al. (1982) Interleukin-1, a potential regulator of fibroblast proliferation. J Immunol 128:2177–2182PubMedGoogle Scholar
  96. 96.
    Schwartz BR, Ochs HD, Beatty PG et al. (1985) A monoclonal antibody defined membrane antigen complex is required for neutrophil-neutrophil aggregation. Blood 65:1553–1556PubMedGoogle Scholar
  97. 97.
    Seeger W, Suttorp N, Hellwig A et al. (1986) Non-cytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human polymorphonuclear leukocytes. J Immunol 137:1286–1293PubMedGoogle Scholar
  98. 98.
    Smiley ML, Hoxie JA, Friedman HM (1985) Herpes simplex virus type I injection of endothelial, epithelial and fibroblast cells induces a receptor for C3b. J Immunol 134:2673–2678PubMedGoogle Scholar
  99. 99.
    Shore A, Leary P, Teitel JM (1986) Comparison of accessory cell functions of endothelium cells and monocytes: IL2 production by T cells and PFC generation. Cell Immunol 100:210–223PubMedCrossRefGoogle Scholar
  100. 100.
    Snyderman R, Pike MC (1984) Chemoattractant receptors on phagocytic cells. Annu Rev Immunol 2:257–281PubMedCrossRefGoogle Scholar
  101. 101.
    Steblay RW (1962) Glomerulonephritis induced in sheep by injection of heterologous glomerular basement membrane and Freund’s complete adjuvant. J Exp Med 116:253–261PubMedCrossRefGoogle Scholar
  102. 102.
    Steeg PS, Moore RN, Johnson HM (1982) Regulation of murine Ia antigen expression by a lymphokine with immune interferon activity. J Exp Med 156:1780–1786PubMedCrossRefGoogle Scholar
  103. 103.
    Stern DM, Bank I, Nawroth PP et al. (1985) Selfregulation of procoagulant events on the endothelial cell surface. J Exp Med 162:1223–1235PubMedCrossRefGoogle Scholar
  104. 104.
    Stolden AM, Guinan EC, Fiers W et al. (1986) Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am J Pathol 123:16–24Google Scholar
  105. 105.
    Sundsmo JS, Fair DS (1983) Relationship among the complement, kinin, coagulation and fibrinolytic systems. Springer Semin Immunopathol 6:231–258PubMedCrossRefGoogle Scholar
  106. 106.
    Theofilopoulos AN, Dixon FJ (1981) Etiopathogenesis of murine systemic lupus erythematosus. Immunol Rev 55:179–216PubMedCrossRefGoogle Scholar
  107. 107.
    Till G, Ward PA (1986) Systemic complement activation and acute lung injury. Fed Proc 45:13–18PubMedGoogle Scholar
  108. 108.
    Tonnesen MG, Smedly LA, Henson PM (1984) Neutrophil-endothelial cell interactions. Modulations of neutrophil adhesiveness induced by complement fragments C5a and C5adesArg and formyl-methionyl-leucyl-phenylalanine in vitro. J Clin Invest 74:1581–1592PubMedCrossRefGoogle Scholar
  109. 109.
    Trinchieri G, Perussia B (1985) Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today 6:131–136CrossRefGoogle Scholar
  110. 110.
    Valentijn RM, Faber WR, Lai A et al. (1982) Immune complexes in leprosy patients from an endemic and a nonendemic area and a longitudinal study of the relationship between complement breakdown products and the clinical activity of erythema nodosum leprosum. Clin Immunol Immunopathol 22:194–202PubMedCrossRefGoogle Scholar
  111. 111.
    Van Oeveren W, Kazatchkine MD, Descamps-Latscha B et al. (1985) Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. J Thorac Cardiovasc Surg 888–899Google Scholar
  112. 112.
    Vlaicu R, Niculescu F, Rus HG et al. (1985) Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 57:163–170PubMedCrossRefGoogle Scholar
  113. 113.
    Vogt A, Rohrbach R, Shimuzu F et al. (1982) Interaction of cationized antigen with rat glomerular basement membrane. Kidney Int 22:27–35PubMedCrossRefGoogle Scholar
  114. 114.
    Wilson CB, Dixon FJ (1981) The renal response to immunological injury. In: Brenner BM, Rector FC Jr (eds) The kidney. Saunders, Philadelphia, pp 1237–1350Google Scholar
  115. 115.
    Wilson JG, Wong WW, Schur PH et al. (1982) Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Engl J Med 307:981–986PubMedCrossRefGoogle Scholar
  116. 116.
    Wright SD, Silverstein SC (1982) Tumor promoting phorbol esters stimulate C3b and C3bi receptor- mediated phagocytosis in cultured human monocytes. J Exp Med 156:1149–1161PubMedCrossRefGoogle Scholar
  117. 117.
    Zubler RH, Lambert PH (1978) Detection of immune complexes in human diseases. Prog Allergy 24:1–48PubMedGoogle Scholar
  118. 118.
    Ziccardi RJ (1983) The first component of human complement (C1): activation and control. Springer Semin Immunopathol 6:213–230PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • M. D. Kazatchkine
  • P. S. Seifert
  • U. E. Nydegger

There are no affiliations available

Personalised recommendations